Adagio Therapeutics
NASDAQ: IVVDWaltham, US · Founded 2020 · Delaware corporation · 3 known investors
Biotech
Founders & leadership
Adagio Therapeutics was founded in 2020 by Tillman U. Gerngross.
TU
Tillman U. GerngrossFounder
LC
Lynn ConnollyExecutive
EK
Eric KimbleExecutive
HG
Halley GilbertExecutive
RD
Rebecca DaboraExecutive
EH
Ellie HershbergerExecutive
JH
Jane HendersonExecutive
Board
TM
Terrance McGuireBoard director
AR
RR
Rene RussoBoard director
HM
Howard MayerBoard director
PC
Philip ChaseBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$489.1M disclosed across 4 rounds · 2020–2022
▶$23.7MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
▶$23.7MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael S. WyzgaDirector
- Fred DriscollExecutive Officer
- Tamsin BerryDirector
- Christine LindenboomDirector
- Terry McGuireDirector
- Rebecca DaboraExecutive Officer
- Marc EliaDirector
- Jill AndersenExecutive Officer
- Clive A. MeanwellDirector
- David HeringExecutive Officer, Director
- Ellie HershbergerExecutive Officer
- Tom HeymanDirector
- Offering amount
- $23.7M
- Amount sold
- $23.7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$335.5MraisedApr 2021 · 36 investors · BiotechnologyRule 506(b)
▶$335.5MraisedApr 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lynn ConnollyExecutive Officer
- Eric KimbleExecutive Officer
- Halley GilbertExecutive Officer
- Terrance McGuireDirector
- Rebecca DaboraExecutive Officer
- Rene RussoDirector
- Howard MayerDirector
- Philip ChaseDirector
- Ellie HershbergerExecutive Officer
- Ajay RoyanDirector
- Tillman U. GerngrossExecutive Officer, Director
- Jane HendersonExecutive Officer
- Laura WalkerExecutive Officer
- Offering amount
- $335.5M
- Amount sold
- $335.5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$80MraisedNov 2020 · 16 investors · BiotechnologyRule 506(b)
▶$80MraisedNov 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Halley GilbertExecutive Officer
- Howard MayerDirector
- Marc EliaDirector
- Rene RussoDirector
- Terrance G. McGuireDirector
- Ajay RoyanDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$49.9MraisedNov 2020 · 24 investors · BiotechnologyRule 506(b)
▶$49.9MraisedNov 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Halley GilbertExecutive Officer
- Terrance G. McGuireDirector
- Rene RussoDirector
- Marc EliaDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Ajay RoyanDirector
- Howard MayerDirector
- Offering amount
- $49.9M
- Amount sold
- $49.9M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Adagio Therapeutics?
- Adagio Therapeutics was founded by Tillman U. Gerngross in 2020.
- Who are Adagio Therapeutics's investors?
- Adagio Therapeutics's investors include Mithril Capital Management, Polaris Partners, Veltro Argento.
- How much funding has Adagio Therapeutics raised?
- Adagio Therapeutics has disclosed $489.1M raised across 4 rounds.
- Where is Adagio Therapeutics headquartered?
- Adagio Therapeutics is headquartered in Waltham, US.